Dennis G. Podlesak has served as chairman of our board of directors since December 2008. Mr. Podlesak is the Chief Executive Officer and Managing Partner of Canaan Partners’ Axceliux LLC, and is an Advisory Partner of Domain Associates, LLC which he joined in November 2007, both of which are life science-focused venture capital firms. Mr. Podlesak previously served as the Chairman of the board of Tobira Therapeutics, a publicly traded biopharmaceutical company that was acquired by Allergan plc. Mr. Podlesak also served on the board of Avanir Pharmaceuticals, a publicly traded biopharmaceutical company, through its acquisition by Otsuka Pharmaceuticals, and was a founding board member of Rightcare Solutions, which was acquired by Cardinal Health. Mr. Podlesak was also the founder and the Chief Executive Officer of Calixa Therapeutics, Inc., a privately held biopharmaceutical company that was acquired by Cubist Pharmaceuticals, and Mr. Podlesak was the Executive Chairman of Corthera, Inc., a privately held biopharmaceutical company which was acquired by Novartis AG. Earlier in his career, Mr. Podlesak served as the Founder and Chief Executive Officer of Cerexa, Inc., a privately held biotechnology company, which became a wholly owned subsidiary of Forest Laboratories, Inc. after being acquired by Forest. Prior to Cerexa, Mr. Podlesak served as the Chief Executive Officer of Peninsula Pharmaceuticals Inc., a privately held pharmaceutical company, and led the sale of Peninsula to Johnson & Johnson’s Ortho-McNeil Pharmaceutical subsidiary. Prior to joining Peninsula, Mr. Podlesak held various executive management positions at Novartis AG, a publicly traded healthcare company, Allergan, plc, a publicly traded healthcare company and Smith Kline Beecham (now GlaxoSmithKline plc, a publicly traded pharmaceutical company). Mr. Podlesak received a B.A. and an M.B.A. from Pepperdine University, and has completed postgraduate studies at the Wharton School, University of Pennsylvania.
What is Dennis Podlesak's net worth?
The estimated net worth of Dennis Podlesak is at least $1.56 million as of September 16th, 2022. Mr. Podlesak owns 75,763 shares of Syndax Pharmaceuticals stock worth more than $1,558,445 as of April 25th. This net worth approximation does not reflect any other investments that Mr. Podlesak may own. Learn More about Dennis Podlesak's net worth.
How do I contact Dennis Podlesak?
Has Dennis Podlesak been buying or selling shares of Syndax Pharmaceuticals?
Dennis Podlesak has not been actively trading shares of Syndax Pharmaceuticals during the last ninety days. Most recently, Dennis Podlesak sold 11,975 shares of the business's stock in a transaction on Friday, September 16th. The shares were sold at an average price of $23.43, for a transaction totalling $280,574.25. Following the completion of the sale, the director now directly owns 75,763 shares of the company's stock, valued at $1,775,127.09. Learn More on Dennis Podlesak's trading history.
Who are Syndax Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Syndax Pharmaceuticals?
In the last year, insiders at the sold shares 6 times. They sold a total of 294,997 shares worth more than $6,006,050.17. The most recent insider tranaction occured on August, 9th when Director Briggs Morrison sold 52,855 shares worth more than $965,660.85. Insiders at Syndax Pharmaceuticals own 4.1% of the company.
Learn More about insider trades at Syndax Pharmaceuticals. Information on this page was last updated on 8/9/2023.
